RichardAlanFurieMD

PubMed

• Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.
  Scott R P McDonnell, Van Anh Nguyen, Noah M Walton, Carsten Merkwirth, Feng Hong, Deborah Berg, Elena Tomaselli Muensterman, Richard A Furie> ;Lupus Science & Medicine. 2024 Mar 7
• 1 citations
  The development of litifilimab (BIIB 059) for cutaneous and systemic lupus erythematosus.
  Young Min Cho, Richard Furie> ;Immunotherapy. 2024 Jan 1
• 29 citations
  EULAR recommendations for the management of systemic lupus erythematosus: 2023 update.
  Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N Bruce, Ricard Cervera, Andrea Doria, Tho...> ;Annals of the Rheumatic Diseases. 2024 Jan 2
• Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis: A Case Series.
  Angel Chen, Richard Furie, Sonali Narain, Galina S Marder, Snyder, M.> ;Journal of Clinical Rheumatology. 2024 Jan 1
• 1 citations
  Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
  Hans-Joachim Anders, Richard Furie, Ana Malvar, Ming-Hui Zhao, Keiju Hiromura, Julia Weinmann-Menke, Yulia Green, Angela Jones-Leone, Daniela Negrini, Roger A Levy, Li...> ;Nephrology, Dialysis, Transplantation. 2023 Nov 30
• 1 citations
  Belimumab treatment of adult idiopathic inflammatory myopathy.
  Galina Marder, Tam Quach, Preeya Nandkumar, Jimmy Tsang, Todd Levine, Elena Schiopu, Richard Furie, Anne Davidson, Sonali Narain, Priyal Chadha> ;Rheumatology. 2024 Mar 1
• 33 citations
  Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
  Eric F Morand, Edward M Vital, Michelle Petri, Ronald van Vollenhoven, Daniel J Wallace, Marta Mosca, Richard A Furie, Maria E Silk, Christina L Dickson, Gabriella Mes...> ;Lancet. 2023 Mar 25
• 8 citations
  Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
  Eric F Morand, Gabriel Abreu, Richard A Furie, Vera Golder, Raj Tummala> ;Annals of the Rheumatic Diseases. 2023 May 1
• 28 citations
  A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
  Kenneth C Kalunian, Richard Furie, Eric F Morand, Ian N Bruce, Susan Manzi, Yoshiya Tanaka, Kevin Winthrop, Ihor Hupka, Lijin Jinny Zhang, Shanti Werther, Gabriel Abre...> ;Arthritis & Rheumatology. 2023 Feb 1
• 13 citations
  Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
  Richard Furie, Brad H Rovin, Frédéric Houssiau, Gabriel Contreras, Y K Onno Teng, Paula Curtis, Yulia Green, Mohamed Okily, Anuradha Madan, David A Roth> ;Clinical Journal of the American Society of Nephrology. 2022 Nov 1
• An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
  Naureen Osman, Richard Furie, Ahmed, A.> ;Expert Review of Clinical Immunology. 2022 Nov 1
• 1 citations
  Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.
  Yen Lin Chia, Raj Tummala, Tu H Mai, Tomas Rouse, Katie Streicher, Wendy I White, Eric F Morand, Richard A Furie> ;Journal of Clinical Pharmacology. 2022 Sep 1
• 6 citations
  Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
  Ian N Bruce, Ronald F van Vollenhoven, Eric F Morand, Richard A Furie, Susan Manzi, William B White, Gabriel Abreu, Raj Tummala> ;Rheumatology. 2023 Apr 3
• 9 citations
  B cell-targeted therapies in systemic lupus erythematosus.
  Leah Arbitman, Richard Furie, Himanshu Vashistha> ;Journal of Autoimmunity. 2022 Oct 1
• 2 citations
  Controversies in Systemic Lupus Erythematosus 2021: Changing the Paradigm in the Management of Lupus Nephritis.
  Sabrina Valeria Porta, Antoine Enfrein, Frédéric Houssiau, Mercedes García, Richard Furie, Brad H Rovin, Graciela S Alarcón, Bernardo A Pons-Estel, Guillermo J Pons-Estel> ;Journal of Clinical Rheumatology. 2022 Jun 1
• 10 citations
  Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
  Ian N Bruce, Richard A Furie, Eric F Morand, Susan Manzi, Yoshiya Tanaka, Kenneth C Kalunian, Joan T Merrill, Patricia Puzio, Emmanuelle Maho, Christi Kleoudis, Marius...> ;Annals of the Rheumatic Diseases. 2022 Jul 1
• 11 citations
  Biological impact of iberdomide in patients with active systemic lupus erythematosus.
  Peter E Lipsky, Ronald van Vollenhoven, Thomas Dörner, Victoria P Werth, Joan T Merrill, Richard Furie, Milan Petronijevic, Benito Velasco Zamora, Maria Majdan, Fedra ...> ;Annals of the Rheumatic Diseases. 2022 Apr 27
• 7 citations
  Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus.
  Murray B Urowitz, Cynthia Aranow, Yumi Asukai, Damon L Bass, Ian N Bruce, Deven Chauhan, Maria Dall'Era, Richard Furie, Norma Lynn Fox, Jennifer A Gilbride, Anne Hamme...> ;Arthritis Care & Research. 2022 Nov 1
• 65 citations
  Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.
  David Jayne, Brad Rovin, Eduardo F Mysler, Richard A Furie, Frederic A Houssiau, Teodora Trasieva, Jacob Knagenhjelm, Erik Schwetje, Yen Lin Chia, Raj Tummala, Cathari...> ;Annals of the Rheumatic Diseases. 2022 Apr 1
• 21 citations
  Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and ...
  Morand, E., Bruce, I., Vital, E., Dall'Era, M., Maho, E., Pineda, L., Tummala, R., Furie, R.> ;The Lancet. Rheumatology. 2022 Apr 1
• 42 citations
  Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III tr...
  Edward M Vital, Joan T Merrill, Eric F Morand, Richard A Furie, Ian N Bruce, Yoshiya Tanaka, Susan Manzi, Kenneth C Kalunian, Rubana N Kalyani, Katie Streicher, Gabrie...> ;Annals of the Rheumatic Diseases. 2022 Jul 1
• 18 citations
  Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.
  Ronald van Vollenhoven, Anca D Askanase, Andrew S Bomback, Ian N Bruce, Angela Carroll, Maria Dall'Era, Mark Daniels, Roger A Levy, Andreas Schwarting, Holly A Quasny,...> ;Lupus Science & Medicine. 2022 Mar 1
• 3 citations
  Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe...
  O'Quinn, S., Morand, E., Schwetje, E., Abreu, G., Tummala, R., Strand, V., Furie, R., Kalunian, K.> ;The Lancet. Rheumatology. 2022 Mar 1
• 2 citations
  High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership.
  Philip M Carlucci, Jessica Li, Andrea Fava, Kristina K Deonaraine, David Wofsy, Judith A James, Chaim Putterman, Betty Diamond, Anne Davidson, Derek M Fine, Jose Monro...> ;Rheumatology. 2022 Nov 2
• 10 citations
  Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
  Richard A Furie, Douglas R Hough, Allison Gaudy, Ying Ye, Shimon Korish, Nikolay Delev, Michael Weiswasser, Xiaojiang Zhan, Peter H Schafer, Victoria P Werth> ;Lupus Science & Medicine. 2022 Feb 1
• Join now to see all

Journal Articles

• Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis  
  Richard Furie, Brad H Rovin, The New England Journal of Medicine

Lectures

• 6th Annual Perspectives in Rheumatic Diseases 
  Global Academy for Medical Education (Elsevier), Las Vegas, Nevada - 9/20/2013
• Advances in B Cell Biology: Rheumatoid Arthritis, Systemic Lupus Erythematosus, & Vasculitis 
  Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Scottsdale, Arizona - 2/18/2012